The abstract is read at the publisher; the summary is JClub's.
Invasive lobular carcinoma remains understudied in systemic therapy evidence, leaving its E-cadherin loss, diffuse growth, and metastatic tropism underrepresented in histology-agnostic trials.
- Why it matters: Most therapeutic trials enroll mainly invasive ductal carcinoma and rarely stratify by histology, so ILC-specific biology is not well reflected in treatment recommendations.
- What they did: This Review synthesizes key molecular alterations and emerging targets in ILC, highlighting preclinical subtype-specific vulnerabilities and proposing histology-specific, multilayered strategies alongside endocrine therapy.
- The result: It argues that future trials with prespecified ILC cohorts, tailored endpoints, and parallel patient and patient-derived model testing could accelerate development and evaluation of ILC-targeted therapeutics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.